News Room
News Releases
-
- Apr. 19, 2019 (PDF/113KB)Finances
-
Sumitomo Dainippon Pharma Revises Financial Forecasts
-
- Apr. 19, 2019Finances
-
Posted Video of Mid-term Business Plan 2022 [Webcast]
-
- Apr. 11, 2019 (PDF/2,177KB)Finances
-
Presentation Material (Mid-term Business Plan 2022)
-
- Apr. 11, 2019 (PDF/83KB)Finances
-
Sumitomo Dainippon Pharma Announces Mid-term Business Plan 2022(FY2018 - FY2022)
-
- Apr. 09, 2019 (PDF/167KB)R&D
-
Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 1) in Japan for the Treatment of Type 2 Diabetes
-
- Apr. 09, 2019 (PDF/101KB)R&D
-
GHIT Fund Awards Grant for Continuing Development of Malaria Vaccine Discovered by Ehime University and Sumitomo Dainippon Pharma
-
- Apr. 05, 2019 (PDF/143KB)R&D
-
Five Partners Commence Joint R&D on Renal Regenerative Medicine
-
- Apr. 02, 2019 (PDF/81KB)R&D
-
Sumitomo Dainippon Pharma Submits an Application of RETHIO for an Additional Indication of Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma
-
- Mar. 28, 2019 (PDF/118KB)Corporate
-
AlphaNavi Pharma Established as a Carve-Out Business Venture from Sumitomo Dainippon Pharma with Investment
-
- Mar. 26, 2019 (PDF/49KB)Products
-
Sumitomo Dainippon Pharma Receives Approval in Japan for RETHIO for Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation
Documents for Press
-
- Dec. 02, 2013 (PDF/414KB)R&D
-
Presentation material of press conference (Healios and DSP: Alliance for Japanese market-iPS cell technology into practical use-)